<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously shown that treatment with selective kappa-opioid receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> BRL 52537 hydrochloride [(+/-)-1-(3,4-dichlorophenyl) <z:chebi fb="9" ids="46887">acetyl</z:chebi>-2-(1-pyrrolidinyl) methylpiperidine] (1) has a long therapeutic window for providing ischemic neuroprotection and (2) attenuates <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-evoked nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) production in vivo in rats </plain></SENT>
<SENT sid="1" pm="."><plain>Neuronally derived NO has been shown to be deleterious in the male, but not in the female, <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of focal <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine if the agent fails to protect ischemic brain when neuronal NO synthase (nNOS) is genetically deleted in male, but not female, mice </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="2" ids="5615">Halothane</z:chebi>-anesthetized adult male and female nNOS null mutants (nNOS(-/-)) and the genetically matched <z:mp ids='MP_0002169'>wildtype</z:mp> (WT) strain were subjected to transient (2 h) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> by the intraluminal filament technique </plain></SENT>
<SENT sid="4" pm="."><plain>Vehicle or BRL 52537 treatment with continuous intravenous infusion was instituted at the <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion and continued for 22 h </plain></SENT>
<SENT sid="5" pm="."><plain>In WT male mice, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes measured at 72 h of reperfusion were robustly decreased with BRL 52537 treatment </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, BRL 52537 did not decrease <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in male nNOS(-/-) mice </plain></SENT>
<SENT sid="7" pm="."><plain>BRL 52537 had no effect in the WT or nNOS(-/-) female mice </plain></SENT>
<SENT sid="8" pm="."><plain>These data support that BRL 52537's mechanism of neuroprotection in vivo is through attenuation of nNOS activity and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-evoked NO production </plain></SENT>
<SENT sid="9" pm="."><plain>Neuroprotective effects of BRL 52537 are lost in the male when nNOS is not present; therefore, BRL 52537 likely acts upstream from NO generation and its subsequent neurotoxicity </plain></SENT>
</text></document>